Gastric And Gastroesophageal Junction Cancers

Adding sintilimab to chemotherapy improved survival compared with placebo among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, phase 3 study results published in JAMA showed.

Two different treatment regimens showed efficacy among patients with gastroesophageal cancers, according to study results presented during an ASCO Plenary Series session.